- Stocks
- Healthcare
- NASDAQ: CTMX

Price (delayed)

$1.79

Market cap

$118.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.51

Enterprise value

-$62.04M

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics,

The gross profit is up by 42% year-on-year and by 34% since the previous quarter

CTMX's revenue is up by 42% year-on-year and by 34% since the previous quarter

CTMX's quick ratio has dropped by 62% year-on-year and by 25% since the previous quarter

What are the main financial stats of CTMX

Market
Valuations
Earnings

Shares outstanding

66.23M

Market cap

$118.55M

Enterprise value

-$62.04M

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

2.21

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-1.17

Revenue

$53.16M

EBIT

-$99.32M

EBITDA

-$93.46M

Free cash flow

-$112.53M

Per share
Balance sheet
Liquidity

EPS

-$1.51

Free cash flow per share

-$1.71

Book value per share

-$1.3

Revenue per share

$0.81

TBVPS

$3.94

Total assets

$260.89M

Total liabilities

$346.64M

Debt

$13.98M

Equity

-$85.75M

Working capital

$84.49M

Debt to equity

-0.16

Current ratio

1.55

Quick ratio

1.51

Net debt/EBITDA

1.93

Margins
Efficiency
Dividend

EBITDA margin

-175.8%

Gross margin

100%

Net margin

-186.8%

Operating margin

-190.6%

Return on assets

-38%

Return on equity

-666.3%

Return on invested capital

-649.4%

Return on capital employed

-91.7%

Return on sales

-186.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the CytomX Therapeutics stock price performed over time

Intraday

5.29%

1 week

-2.72%

1 month

-16.74%

1 year

-33.46%

YTD

11.88%

QTD

11.88%

How have CytomX Therapeutics's revenue and profit performed over time

Revenue

$53.16M

Gross profit

$53.16M

Operating income

-$101.34M

Net income

-$99.32M

Gross margin

100%

Net margin

-186.8%

CTMX's net margin is up by 43% since the previous quarter and by 40% year-on-year

The gross profit is up by 42% year-on-year and by 34% since the previous quarter

CTMX's revenue is up by 42% year-on-year and by 34% since the previous quarter

The company's operating margin rose by 42% QoQ and by 39% YoY

What is CytomX Therapeutics's growth rate over time

What is CytomX Therapeutics stock price valuation

P/E

N/A

P/B

N/A

P/S

2.21

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-1.17

The EPS has grown by 25% from the previous quarter and by 17% YoY

The stock's P/S is 72% less than its 5-year quarterly average of 8.0 and 26% less than its last 4 quarters average of 3.0

CTMX's revenue is up by 42% year-on-year and by 34% since the previous quarter

How efficient is CytomX Therapeutics business performance

The ROIC has shrunk by 158% QoQ

CTMX's ROE has dropped by 86% since the previous quarter

The ROS has grown by 43% from the previous quarter and by 40% YoY

CTMX's return on assets is down by 27% year-on-year but it is up by 18% since the previous quarter

What is CTMX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CTMX.

How did CytomX Therapeutics financials performed over time

CTMX's total assets is 25% less than its total liabilities

The company's total liabilities has surged by 75% QoQ

CTMX's quick ratio has dropped by 62% year-on-year and by 25% since the previous quarter

CTMX's debt is 116% greater than its equity

The debt to equity has dropped by 130% since the previous quarter but it has soared by 100% year-on-year

CTMX's debt is down by 23% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.